Focused On-demand Library for Sphingosine 1-phosphate receptor 2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O95136

UPID:
S1PR2_HUMAN

ALTERNATIVE NAMES:
Endothelial differentiation G-protein coupled receptor 5; Sphingosine 1-phosphate receptor Edg-5

ALTERNATIVE UPACC:
O95136; Q86UN8

BACKGROUND:
Sphingosine 1-phosphate receptor 2, alternatively named Endothelial differentiation G-protein coupled receptor 5, is a key player in the sphingosine 1-phosphate (S1P) signaling pathway. It binds to S1P, a bioactive lysophospholipid, eliciting a wide range of physiological responses in cells and tissues. Additionally, it acts as a receptor for the chemokine-like protein FAM19A5, influencing vascular smooth muscle cell proliferation and migration.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in mediating processes such as cell proliferation and apoptosis suppression, Sphingosine 1-phosphate receptor 2 represents a promising target for drug discovery. Its association with Deafness, autosomal recessive, 68, underscores the therapeutic potential in treating sensorineural hearing loss and underscores the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.